Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Etoposide 154Carboplatin 142Cisplatin 104Topotecan 74durvalumab 48atezolizumab 46Irinotecan 44pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 29anlotinib 23PM 01183 22Gemcitabine 21Drug Therapy 20apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Bevacizumab 13amrubicin 11Magnetic Resonance Spectroscopy 11Cyclophosphamide 11rovalpituzumab tesirine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Small Cell Lung Carcinoma × onvansertib × Clear all
NCT05450965 2025-12-17

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

University of Maryland, Baltimore

Phase 2 Recruiting
37 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡